IMPACT OF KRAS AND BRAF GENE MUTATION STATUS ON OUTCOMES FROM THE PHASE III AGITG MAX TRIAL OF CAPECITABINE (C) ALONE OR IN COMBINATION WITH BEVACIZUMAB (B) +/- MITOMYCIN C (M) IN ADVANCED COLORECTAL CANCER (CRC) Conference Paper uri icon

authors

  • Price, TJ
  • Hardingham, J
  • Lee, C
  • Weickhardt, A
  • Townsend, A
  • Wrin, JW
  • Shivasami, A
  • Cummins, M
  • Murone, C
  • Tebbutt, N

publication date

  • October 1, 2010